Eli Lilly and vs Johnson & Johnson: Fair Value & Quality
Both stocks run through our valuation models. Here is how Eli Lilly and (LLY) and Johnson & Johnson (JNJ) compare, as of Aug 14, 2026.
As of Aug 14, 2026, Fair Value Calculator sees Johnson & Johnson as the less overvalued of the two: Eli Lilly and trades at $1,209 versus a fair value of $389 (-68%), while Johnson & Johnson trades at $262 versus $169 (-36%).
Eli Lilly and
LLY · USD · Health Care
-68%
upside to fair value
overvalued
Price$1,209
Fair Value$389
Quality69/100
Johnson & Johnson
JNJ · USD · Health Care
-36%
upside to fair value
overvalued
Price$262
Fair Value$169
Quality81/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Eli Lilly andJohnson & Johnson
Valuation
42.2×P/E (TTM)29.4×
14.67×P/S (TTM)6.34×
39.94×P/B7.49×
30.2×EV/EBITDA18.4×
1.54×PEG4.95×
0.5%Dividend yield2.0%
$6.23Dividend per share$5.20
Profitability
35%Net margin22%
49%Operating margin27%
107%Return on equity26%
21%Return on assets8%
Growth
56%Revenue growth (YoY)10%
31.7%Avg. growth/yr (3Y)5.6%
21.6%Avg. growth/yr (5Y)2.7%
Balance & size
1.54×Debt / equity0.48×
$1.1TMarket cap$611B
mixedGrowth qualityhealthy
Eli Lilly and leads: 8 to 6 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Eli Lilly andof which business quality 65 · market factors 83Johnson & Johnsonof which business quality 76 · market factors 84
ProfitabilityMargins and returns on capital today
85
74
Quality GrowthAre margins and returns improving?
86
73
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
15
87
Low VolatilityCalm price path (market factor)
77
96
MomentumPrice trend over the last 3–12 months (market factor)
79
69
52W MomentumDistance to the 52-week high (market factor)
97
94
Net IssuanceBuybacks instead of dilution
93
90
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Eli Lilly and
DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375
26 of 26 models see the stock below the current price.
Johnson & Johnson
DCF Models$171
Earnings-Based$73.34
Dividend Discount$93.41
Multiples$163
Asset-Based$22.70
Growth DCF$129
Economic Profit$102
Growth Earnings$207
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,209 = current price (white tick)
Johnson & Johnson
Bear $106Fair Value $169Bull $255
$262 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Eli Lilly and · Health Care
Quality score69 · Top 25%
Fair value upside-68% · bottom 25%
Johnson & Johnson · Health Care
Quality score81 · Top 25%
Fair value upside-36% · below median
Bottom line
As of Aug 14, 2026, Fair Value Calculator sees Johnson & Johnson as the less overvalued of the two: Eli Lilly and trades at $1,209 versus a fair value of $389 (-68%), while Johnson & Johnson trades at $262 versus $169 (-36%).
Johnson & Johnson has the higher quality score (81/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
